Evidence map›Paper›PMID 41815150›Full record

ArticleTranslational cancer research2026

Yan Qin, Minghui Zhao, Jingxin Zhang, Yuhe Pei, Siyuan Suo, Min Wu, Yan Shi, Feixiang Wu, Zhou Shen, Hao Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yan Qin *Central Laboratory, Affiliated Hospital of Hebei University, Baoding, China.
Minghui Zhao *Department of Radiology, Affiliated Hospital of Hebei University, Baoding, China.
Jingxin ZhangClinical Medical College, Hebei University, Baoding, China.
Yuhe PeiClinical Medical College, Hebei University, Baoding, China.
Siyuan SuoClinical Medical College, Hebei University, Baoding, China.
Min WuCentral Laboratory, Affiliated Hospital of Hebei University, Baoding, China.
Yan ShiDepartment of Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Feixiang WuCentral Laboratory, Affiliated Hospital of Hebei University, Baoding, China.
Zhou ShenCentral Laboratory, Affiliated Hospital of Hebei University, Baoding, China.
Hao LiCentral Laboratory, Affiliated Hospital of Hebei University, Baoding, China.
Hao ZhangDepartment of Oncology, The 8th People's Hospital of Hengshui, Hengshui, China.
Lan ZhangIntegrated Traditional and Western Medicine, Affiliated Hospital of Hebei University, Baoding, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The abnormal proliferation and migration of endothelial cells is closely associated with vascular growth, which regulates angiogenesis and cancer cell progression. Methods: To identify Results: Exogenously administered Sal-miR-58 was detected in mouse tissues and HUVEC cultures, demonstrating high stability under boiling and acidic conditions. It inhibited cancer development Conclusions: Sal-miR-58 exerts anti-tumor effects by targeting KLF3 messenger RNA (mRNA). This targeting inhibits abnormal HUVEC proliferation and migration

Indexed as

Angiogenesisanti-tumorproliferationSalvia miltiorrhiza-derived miR-58 (Sal-miR-58)Salvia miltiorrhiza (S. miltiorrhiza)

Identifiers

PMID41815150
PMCPMC12971582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.